Frontiers in Pharmacology (Feb 2023)
Editorial: Toxicity mechanism and clinical features of PD-1/PD-l1 inhibitors in treatment of cancer, volume II
- Chuqi Lei,
- Xiangyi Kong,
- Xiangyi Kong,
- Ryan J. Sullivan,
- Caisheng Wu,
- Caisheng Wu,
- Dawei Wang,
- Lin Zhang,
- Lin Zhang,
- Lin Zhang
Affiliations
- Chuqi Lei
- Department of Breast Surgical Oncology, National Cancer Center, National Clinical Research Center for Cance, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
- Xiangyi Kong
- Department of Breast Surgical Oncology, National Cancer Center, National Clinical Research Center for Cance, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
- Xiangyi Kong
- Department of Breast Surgical Oncology, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China
- Ryan J. Sullivan
- Center for Melanoma, Massachusetts General Hospital Cancer Center, Harvard Medical School, Harvard University, Boston, MA, United States
- Caisheng Wu
- Laboratory Animal Center, Xiamen University, Xiamen, China
- Caisheng Wu
- School of Pharmaceutical Sciences, Xiamen University, Xiamen, China
- Dawei Wang
- Department of Urology, Ruijin Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China
- Lin Zhang
- Institute of Artificial Intelligence, Hefei Comprehensive National Science Center, Hefei, China
- Lin Zhang
- Suzhou Industrial Park Monash Research Institute of Science and Technology, Suzhou, China
- Lin Zhang
- School of Population Medicine and Public Health, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China
- DOI
- https://doi.org/10.3389/fphar.2023.1136373
- Journal volume & issue
-
Vol. 14
Abstract
No abstracts available.Keywords